Novel trisaccharide based phospholipids as immunomodulators.
Fiche publication
Date publication
juin 2019
Journal
International immunopharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MULLER Sylviane
Tous les auteurs :
Bonam SR, Bhunia D, Muller S, Nerella SG, Alvala M, Halmuthur Mahabalarao SK
Lien Pubmed
Résumé
A focused library of novel mannosylated glycophospholipids was synthesized employing imidate coupling and H-phosphate phosphorylation methods. All novel glycophospholipids were evaluated for their receptor interactions by molecular docking studies. Docking studies revealed dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) specific interaction of the glycophospholipid ligand P4 acts, which was further confirmed by in vitro DC-SIGN expression on monocyte-derived dendritic cells (MoDCs). Further, in vitro and in vivo immunomodulatory activity among the six compounds (P1-P6) examined, compound P4 displayed good immunopotentiation and adjuvant properties as indicated by the induced cytokine expression and enhanced ovalbumin (OVA) specific antibody (IgG) titers. Phosphatidylinositol mannosides (PIMs) analogues in the present study enforced the immunomodulatory properties, truncating parent PIMs or tailor-made of PIMs may bring the novel efficacious molecules, which will be useful in vaccine preparation against different diseases.
Mots clés
Adjuvanticity, Glycophospholipids, Immunomodulators, Innate immunity, Mannosyl trisaccharide, Vaccines
Référence
Int. Immunopharmacol.. 2019 Jun 11;74:105684